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Chris Farentinos:This is very important information
for patients and counselors to have. Patients can under-
stand their reactions in terms of, ‘By taking this
drug I stimulated my brain so much I’ve kind of extin-
guished its ability to produce certain neurotransmit-
ters, and once I stop taking the drug, dysphoria will
arise and that creates a cycle of addiction.’ And the
counselor can have more empathy for the client: It’s
not that the clients are not trying to get better or that
they are bad people, but they feel so bad after they stop
using the drug that they have to go back. There is also
a neurobiological connection to impulsivity and per-
sonality disorders, so the whole thing fits together.
Doug Ziedonis: From a pragmatic point of view, this
kind of article is useful for stigma-busting with legis-
latures, since they don’t want to pay for habits or
choices. They want to pay only in cases of medical
necessity.
The recovery community agrees with the disease
concept of addiction. Most of the recovery models
people use when working with addicted patients use
some type of bio-psycho-social-spiritual matrix. The
biological part is considered most important in early
stages of recovery, maybe during the first year, because
the patient has to deal with acute withdrawal, depend-
ence, and then protracted withdrawal.
Where the recovery and medical communities
often don’t see eye to eye is when the disease concept
gets translated into a rationale for using medication,
whether it is in the case of dual-diagnosis patients or
even the use of naltrexone to treat opiate addiction.
Naltrexone is a great medication; it can be very use-
ful in treating impaired professionals. But if you
survey average community treatment programs, hardly
any patients are on naltrexone. Methadone is its
own medical model system that doesn’t always link
well with places that use the abstinence model. I have
worked at abstinence programs and have worked at
Yale as medical director of a methadone program. I
favor the use of methadone as part of a treatment con-
tinuum.
Tom Brewster:Therapeutic communities have long
been the most resistant single group to the use of med-
ications for opiate abuse treatment. I think there has
been a movement among providers to utilize methadone
more in our therapeutic communities. There certainly
has been in my community. We actively maintain
patients on the medication and have trained our coun-
selors. Our recovering counselors are abstinence-
oriented individuals: they don’t drink and they cer-
tainly aren’t using illicit substances. They generally
challenge any form of medication, particularly anal-
gesic medication, even when it should be legitimately
used for pain reduction after surgery and so forth. But
our program has embraced methadone despite this
resistance, because of the biological connection described
by Kosten and George.
The information about biology and about med-
ications is useful for patients who are asking to be taken
off methadone. Patients come to me and say, ‘I want
to detox. Methadone is not good. It is a weakness. My
wife wants me off of it, my employer wants me off,
society wants me off, my probation officer wants me
off.’ Corrections workers press patients to feel guilty
about taking a narcotic medicine. They don’t believe
in it. We resist this pressure because we know better.
The relapse rate of those who get off methadone main-
tenance is perilously high. We strongly discourage peo-
ple from going off the medicine.&
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